tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Innovent Biologics Schedules Board Meeting to Review Interim Results

Story Highlights
Innovent Biologics Schedules Board Meeting to Review Interim Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Innovent Biologics ( (HK:1801) ) has shared an announcement.

Innovent Biologics, Inc. has announced that its Board of Directors will hold a meeting on August 27, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.

More about Innovent Biologics

Innovent Biologics, Inc. is a biopharmaceutical company incorporated in the Cayman Islands. The company focuses on the development, manufacturing, and commercialization of biologic drugs for the treatment of cancer, autoimmune, and other major diseases. It is listed on the Stock Exchange of Hong Kong and operates within the healthcare industry.

YTD Price Performance: 154.10%

Average Trading Volume: 24,217,049

Technical Sentiment Signal: Buy

Current Market Cap: HK$159B

For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1